M
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Michael E. Stokes' research focuses on the development of novel therapeutic agents, particularly small molecule inhibitors targeting key cellular pathways involved in disease progression. His work has explored inhibitors of the SARS-CoV-2 3CL protease for COVID-19 treatment and has significantly investigated the role of the eukaryotic initiation factor-2α kinase PERK in cancer metastasis and autoimmune diseases.
Stokes has published on PERK inhibitors, such as HC-5404, demonstrating their potential to block metastatic progression by limiting the survival of quiescent cancer cells and sensitize renal cell carcinoma models to antiangiogenic tyrosine kinase inhibitors. His research also extends to the clinical application and cost-effectiveness of medical treatments, including a comparative analysis of healthcare service utilization and costs for epilepsy management devices. He leads a research group and has a scholarly record indicated by an h-index of 22 and over 3,149 citations across 122 publications.
Metrics
- h-index: 22
- Publications: 122
- Citations: 3,187
Selected Publications
-
CD30+ T-cell lymphoma following Chimeric Antigen Receptor T-cell therapy (CART-cell therapy): Diagnostic uncertainty in a postimmunotherapy setting (2025)
Collaboration Network
Top Collaborators
David Surguladze
FuelCell Energy (United States) (US)
37 shared publications
- A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells
- PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Inhibition of the eukaryotic initiation factor-2α kinase PERK decreases risk of autoimmune diabetes in mice
- A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors.
- Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML
Showing 5 of 37 shared publications
Verónica Calvo
FuelCell Energy (United States) (US)
36 shared publications
- A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells
- PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Inhibition of the eukaryotic initiation factor-2α kinase PERK decreases risk of autoimmune diabetes in mice
- Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors
- Abstract 4010: Inhibition of PERK by HC-5404 sensitizes clear cell renal cell carcinoma tumor models to anti-angiogenic tyrosine kinase inhibitors
Showing 5 of 36 shared publications
Mark J. Mulvihill
FuelCell Energy (United States) (US)
36 shared publications
- A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells
- PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Inhibition of the eukaryotic initiation factor-2α kinase PERK decreases risk of autoimmune diabetes in mice
- Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors
- Abstract 4010: Inhibition of PERK by HC-5404 sensitizes clear cell renal cell carcinoma tumor models to anti-angiogenic tyrosine kinase inhibitors
Showing 5 of 36 shared publications
Kirk A. Staschke
Indiana University School of Medicine
35 shared publications
- A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells
- PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Inhibition of the eukaryotic initiation factor-2α kinase PERK decreases risk of autoimmune diabetes in mice
- Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML
- Inhibition of the Eukaryotic Initiation Factor-2-α Kinase PERK Decreases Risk of Autoimmune Diabetes in Mice
Showing 5 of 35 shared publications
Sho Fujisawa
33 shared publications
- A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells
- PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Abstract 4010: Inhibition of PERK by HC-5404 sensitizes clear cell renal cell carcinoma tumor models to anti-angiogenic tyrosine kinase inhibitors
- Data from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Supplementary Fig. S1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Showing 5 of 33 shared publications
Crissy Dudgeon
FuelCell Energy (United States) (US)
23 shared publications
- PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors.
- Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML
- Abstract 4010: Inhibition of PERK by HC-5404 sensitizes clear cell renal cell carcinoma tumor models to anti-angiogenic tyrosine kinase inhibitors
- 884 PERK inhibitor HC-5404 demonstrates immune-activation and anti-tumor efficacy in combination with anti-PD1 immune checkpoint inhibitor antibody
Showing 5 of 23 shared publications
Eric S. Lightcap
FuelCell Energy (United States) (US)
23 shared publications
- PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors.
- Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML
- Abstract 4010: Inhibition of PERK by HC-5404 sensitizes clear cell renal cell carcinoma tumor models to anti-angiogenic tyrosine kinase inhibitors
- 884 PERK inhibitor HC-5404 demonstrates immune-activation and anti-tumor efficacy in combination with anti-PD1 immune checkpoint inhibitor antibody
Showing 5 of 23 shared publications
Nandita Bose
FuelCell Energy (United States) (US)
23 shared publications
- PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors.
- Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML
- Abstract 4010: Inhibition of PERK by HC-5404 sensitizes clear cell renal cell carcinoma tumor models to anti-angiogenic tyrosine kinase inhibitors
- 884 PERK inhibitor HC-5404 demonstrates immune-activation and anti-tumor efficacy in combination with anti-PD1 immune checkpoint inhibitor antibody
Showing 5 of 23 shared publications
Jennifer Gasparek
20 shared publications
- PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors
- Data from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Supplementary Fig. S1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Supplementary Table ST1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Showing 5 of 20 shared publications
Matthew J. Betzenhauser
20 shared publications
- PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors
- Data from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Supplementary Fig. S1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Supplementary Table ST1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Showing 5 of 20 shared publications
Sharon Huang
20 shared publications
- PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Abstract 4010: Inhibition of PERK by HC-5404 sensitizes clear cell renal cell carcinoma tumor models to anti-angiogenic tyrosine kinase inhibitors
- Data from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Supplementary Fig. S1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Supplementary Table ST1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Showing 5 of 20 shared publications
Nupur Ballal
20 shared publications
- PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Abstract 4010: Inhibition of PERK by HC-5404 sensitizes clear cell renal cell carcinoma tumor models to anti-angiogenic tyrosine kinase inhibitors
- Data from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Supplementary Fig. S1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Supplementary Table ST1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Showing 5 of 20 shared publications
Alan C. Rigby
20 shared publications
- PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Abstract 4010: Inhibition of PERK by HC-5404 sensitizes clear cell renal cell carcinoma tumor models to anti-angiogenic tyrosine kinase inhibitors
- Data from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Supplementary Fig. S1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Supplementary Table ST1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Showing 5 of 20 shared publications
Leyi Shen
19 shared publications
- PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Data from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Supplementary Fig. S1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Supplementary Table ST1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Supplementary Fig.S2 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Showing 5 of 19 shared publications
S. Taylor
19 shared publications
- PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Data from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Supplementary Fig. S1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Supplementary Table ST1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
- Supplementary Fig.S2 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Showing 5 of 19 shared publications
Similar Researchers
Based on overlapping research topics
Kevin Reynolds
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Metabolism and Genetic Disorders
Disease Mechanisms Research
Peter A. Crooks
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Delivery Systems
Metabolism and Genetic Disorders
Susan Harley
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
SARS-CoV-2 and COVID-19 Research
Metabolism and Genetic Disorders
Joseph Asante
University of Arkansas at Little Rock
SARS-CoV-2 and COVID-19 Research
Metabolism and Genetic Disorders
Retrospective Studies
Bailey Cronin
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Metabolism and Genetic Disorders
Disease Mechanisms Research
Suman Kumar Samanta
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Delivery Systems
Metabolism and Genetic Disorders